PharmaResources (Shanghai) Co., Ltd. is a fast-growing CRO/CDMO service provider of drug discovery and API/key intermediates manufacturer. Since the establishment in December of 2007, PharmaResources has built the collaborations with worldwide customers and business partners, with the aim of becoming a leading preclinical service provider and API/key intermediates manufacturer, creating IP and value for our clients.
With headquarter located in the east campus of Zhangjiang Hi-tech Industrial Park, PharmaResources owns a facility of nearly 11,100 square meters space. Rely on a number of advanced equipments including NMR (Bruker 400 MHz), SFC, HPLC, prep-HPLC, Comblflash, LC-MS, LC-MS / MS (API 4000), IR, UV, GC, GC-MS, microwave synthesizer, parallel synthesizer，differential scanning calorimetry (DSC), electron microscope and various kinds of experimental and testing devices, PharmaResources has been focusing on creating a safe, comfortable and scientific working environment for employees. PharmaResources pledges to serve its customers with the highest value and its contributions in efficiency, passion and commitment.
PharmaResources (Kaiyuan) Co., Ltd, the subsidiary of PR., is located in Kaiyuan City, Liaoning Province. PR Kaiyuan), is a GMP certified manufacturer with a pilot plant of 60,000 square meters. The plant is focused on the R&D, manufacture (including CMO service) and sales of advanced intermediates and APIs that are highly demanded in the global market. PharmaResources (Kaiyuan) has several commercial products including Ticagrelor API and intermediates, Levocarnitine API, Peramivir intermediates, Velpatasvir intermediates, Sofosbuvir intermediates etc., some of which have obtained COS certificate of EU and certificates from other countries. .
PharmaResources has nearly 600 employees (including PR (Kaiyuan) plant). Through the continuous efforts, the company has been awarded the titles of “Advanced-technology Service Enterprise” and ”High-tech Enterprise” respectively. Dr. Ping Chen (CEO) and Dr. Zhenwei Cai (Senior VP of Chemistry) are senior experts in drug discovery industry from abroad. Both Dr. Chen and Dr. Cai are awarded with the “Thomas Edison Patent Award” issued by R&D Council of New Jersy in 2008 and 2011 respectively for their outstanding contributions to novel oncology drug discoveries.
PharmaResources strives to build the corporate culture based on science-focused with continuous innovation, talent training, team building and all the other aspects, all of which are implemented into the company's management system,.
PharmaResources was listed in National Equities Exchange and Quotations (NEEQ) in May of 2016, stock code: 837359.